Online inquiry

IVTScrip™ mRNA-Anti-ITGA4&ITGB7, LDP-02(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10202MR)

This product GTTS-WQ10202MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets ITGA4&ITGB7 gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000885.6; NM_000889.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3676; 3695
UniProt ID P13612; P26010
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ITGA4&ITGB7, LDP-02(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ10202MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15483MR IVTScrip™ mRNA-Anti-MAPT, UCB-0107(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA UCB-0107
GTTS-WQ7478MR IVTScrip™ mRNA-Anti-TGFB, GC-1008(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA GC-1008
GTTS-WQ540MR IVTScrip™ mRNA-Anti-ERBB2, 4D5-8(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA 4D5-8
GTTS-WQ14362MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG7716(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA RG7716
GTTS-WQ12482MR IVTScrip™ mRNA-Anti-IL20, NN-8226(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA NN-8226
GTTS-WQ2059MR IVTScrip™ mRNA-Anti-Canlupfam PDCD1, AH-PD1(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AH-PD1
GTTS-WQ430MR IVTScrip™ mRNA-Anti-AMHR2, 3C23K(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 3C23K
GTTS-WQ2131MR IVTScrip™ mRNA-Anti-CGRP, ALD-403(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ALD-403
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW